Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsThe glycoform of an Antibody-Drug Conjugate (ADC) is a critical determinant of its stability, pharmacokinetics, and therapeutic efficacy. To fully characterize this essential attribute, we offer an ADC Glycoform Analysis Service. This platform utilizes high-resolution mass spectrometry, automated biotransformation mapping, and detailed site-specific glycopeptide analysis. Our service provides you with a comprehensive molecular map, enabling you to understand conjugation impacts, predict in vivo behavior, identify optimal leads, and generate the robust data packages required for successful regulatory submissions.
Antibody-drug conjugates (ADCs) represent a transformative class of targeted therapies. While methods to characterize attributes like drug-to-antibody ratio have advanced, analyzing post-translational modifications such as glycosylation remains challenging. Glycoforms critically affect ADC pharmacokinetics, immunogenicity, and efficacy, but their profiling is hindered by molecular complexity and unstable linkers/payloads. Modern high-resolution LC-MS enables integrated analysis of DAR, payload stability, and glycoforms. This approach is vital for optimizing ADC design, understanding structure-function relationships, and ensuring therapeutic safety and potency.
Fig.1 Schematic representation and mass spectrometry strategies for ADC analysis. 1
Creative Biolabs offers a complete analytical package to de-risk your ADC development. Our detailed characterization of conjugate carbohydrate structures generates actionable insights that link molecular integrity to functional performance. We support optimal lead candidate selection by tracking how conjugation impacts critical quality attributes, such as sialylation and fucosylation levels, which directly govern pharmacokinetics and effector functions like ADCC.
In addition to our specialized Antibody-Drug Conjugate (ADC) Glycoform Analysis, our Therapeutic Antibody Glycan Characterization platform encompasses a broader portfolio of tailored services designed to address the comprehensive glycosylation profiling needs essential for antibody therapeutics development. For further details regarding our service offerings or to discuss potential project-specific solutions, we invite you to contact our team at your convenience.
Our ADC glycoform analysis services leverage advanced analytical platforms to generate precise structural data, facilitating critical assessments for product development, stability evaluation, and quality assurance.
Required Starting Materials: To begin the service, please provide the purified ADC sample along with the full amino acid sequence of the monoclonal antibody, including any known conjugation site information.
Final Deliverables: Upon project completion, you will receive a comprehensive Certificate of Analysis (CoA). This includes chromatographic glycan profiles, deconvoluted mass spectra for Drug-to-Antibody Ratio (DAR) determination, and a structural summary report detailing terminal sugar residues and their specific linkage patterns.
Choose our service for unparalleled depth in ADC characterization. We combine regulatory-aligned workflows with advanced analytical technology to deliver more than just basic profiling. Our unique capability in automated biotransformation mapping uncovers critical, often missed metabolites, providing you with a complete understanding of conjugate stability, safety, and efficacy to de-risk your development path.
"Creative Biolabs' service provided critical insights into the in vivo deconjugation of DAR 6 species. Their high-resolution data enabled an early, strategic pivot in our linker chemistry, saving months of development time." Dr. Marc** A.
"This glycoform analysis was pivotal in selecting our lead candidate with optimal sialylation. The data quality surpassed our previous HPLC-based methods, delivering exceptionally clear and actionable results." Sarah L** W.
"Their advanced mapping platform delivered the exact glycosylation site occupancy data required for our submission package. The seamless integration of intact mass and glycopeptide-level analysis was invaluable." Prof. Robert** K.
Precise glycan analysis is critical for ADC stability, potency, and safety. Our expert team provides end-to-end characterization, from early candidate screening to regulatory submission support. Contact us today for a detailed consultation and a tailored proposal to advance your ADC program with confidence.
Reference
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
